Malaria Prophylactic Drug Tafenoquine brand name Arakoda
1.0 SUBJECT: This is a Request for Information (RFI) ONLY. The U.S. Army Medical Research Acquisition Activity (USAMRAA) located at FT. Detrick, MD, in support of the U.S. Army Medical Materiel Development Activity (USAMMDA), Combat Trauma and Acute Rehabilitation (CTAR), Program Management Office (PMO), located at FT. Detrick, MD, for the purchase of Malaria Prophylactic Drug Tafenoquine brand name Arakoda.
2.0 DISCLAIMER: This RFI is issued solely for information and planning purposes, it does not constitute a solicitation nor does it restrict the Government as to the ultimate acquisition approach. In accordance with FAR 15.201(e), responses to this notice are not offers and cannot be accepted by the Government to form a binding contract. Responses will be used for market research purposes only. Responders are advised that the U.S. Government will not pay for any information or administrative costs incurred in response to this RFI. All costs associated with responding to this RFI will be solely at the interested vendor's expense. Not responding to this RFI does not preclude participation in any future RFP, if one is issued, all information received in response to this RFI that is marked Proprietary, will be handled accordingly. Responses to the RFI will not be returned. At this time, questions concerning the composition and requirements for a future RFP will not be entertained.
This proposed procurement will be under North American Industry Classification System Code (NAICS) 325412 Pharmaceutical Preparation Manufacturing. Business size standard is 1,250 employees.
3.0 DESCRIPTION: This Request for Information (RFI) ONLY is seeking entities interested in providing one (1) commercial lot of ~120,000 tablets (7,500 packages) of Tafenoquine brand name Arakoda immediately, with base Contract Line Item Number (CLIN) and three (3) optional CLINs to procure up to 3,750 packages per CLIN. The USAMMDA PMO requires Tafenoquine brand name Arakoda in order to accomplish User Acceptance (Initial Operational) Testing for the malaria prophylactic drug (Tafenoquine) brand name Arakoda. The goal of this testing is to gain information regarding user compliance of a weekly dosing schedule versus a daily schedule; the suitability of packaging; its ability to be used in multiple operational environments; and a single dose post deployment instead of the current standard of care (SOC) 14 day treatment course. The operational testing will look at the drug‘s performance attributes and usability. User feedback will evaluate U.S. Service Members' preference for a weekly medication, positive or negative side effects compared to the current standard of care prophylactic malaria medications, and general comments on ease of use of the packaging.
Please see Attachment 1, Attachment 2, and Attachment 3 for full RFI details and specifications.
4.0 SUBMISSION INSTRUCTIONS: The Government is seeking sources, Capability Statements, and industry feedback for this requirement for one (1) commercial lot of ~120,000 tablets (7,500 packages) of Tafenoquine brand name Arakoda immediately, with base Contract Line Item Number (CLIN) and three (3) optional CLINs to procure up to 3,750 packages per CLIN. Entities interested in submitting a response must furnish in writing, a 2-3 page (not including cover page, index or list of references) synopsis of their capability to provide the described product, including any necessary lead time. Companies responding to this notice must provide complete contact information (telephone, address, email address). Responders must identify their company's business size (based on the NAICS size standard), business status (i.e., small business, disadvantaged, HUB zone, woman owned, service disabled veteran owned). Please list any feedback accordingly (marked as vendor feedback) following your capability statement. This notice is NOT a request for competitive quotes; no solicitation document is available and telephone requests will not be accepted. However, sources may submit descriptive literature, fully documenting their capability to supply the instruments which shall be considered by the Agency. A determination to compete this procurement based on response(s) to this notice is solely within the discretion of the Government.
5.0 SUBMISSION CONTACT INFORMATION: All Capabilities Statements are to be submitted as an electronic response, in Microsoft Office format and/or Portable Document Format (PDF) to this Request For Information (RFI) Notice NLT Monday, 20 May 2019, 3:00 PM EST. All responses submitted shall be unclassified and MUST be e-mailed. Interested entities shall forward submissions to Ms. Maribel C. Fratina, maribel.c.fratina.civ@mail.mil.
Mail and telephone inquiries will not be accepted or acknowledged and no feedback or evaluations will be provided to companies regarding their submissions.
Maribel C. Fratina, Contract Specialist, Phone 3016197731, Email maribel.c.fratina.civ@mail.mil
